Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

30 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis.
Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, Engle M, Goldberg SV, Phan HTT, Hakim J, Johnson JL, Lourens M, Martinson NA, Muzanyi G, Narunsky K, Nerette S, Nguyen NV, Pham TH, Pierre S, Purfield AE, Samaneka W, Savic RM, Sanne I, Scott NA, Shenje J, Sizemore E, Vernon A, Waja Z, Weiner M, Swindells S, Chaisson RE; AIDS Clinical Trials Group; Tuberculosis Trials Consortium. Dorman SE, et al. Among authors: narunsky k. N Engl J Med. 2021 May 6;384(18):1705-1718. doi: 10.1056/NEJMoa2033400. N Engl J Med. 2021. PMID: 33951360 Free PMC article. Clinical Trial.
Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients.
Diacon AH, Dawson R, Hanekom M, Narunsky K, Maritz SJ, Venter A, Donald PR, van Niekerk C, Whitney K, Rouse DJ, Laurenzi MW, Ginsberg AM, Spigelman MK. Diacon AH, et al. Among authors: narunsky k. Antimicrob Agents Chemother. 2010 Aug;54(8):3402-7. doi: 10.1128/AAC.01354-09. Epub 2010 May 24. Antimicrob Agents Chemother. 2010. PMID: 20498324 Free PMC article. Clinical Trial.
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Diacon AH, Dawson R, du Bois J, Narunsky K, Venter A, Donald PR, van Niekerk C, Erondu N, Ginsberg AM, Becker P, Spigelman MK. Diacon AH, et al. Among authors: narunsky k. Antimicrob Agents Chemother. 2012 Jun;56(6):3027-31. doi: 10.1128/AAC.06125-11. Epub 2012 Mar 19. Antimicrob Agents Chemother. 2012. PMID: 22430968 Free PMC article. Clinical Trial.
Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis.
Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, Pappas F, Phillips PP, Nunn AJ; REMoxTB Consortium. Gillespie SH, et al. N Engl J Med. 2014 Oct 23;371(17):1577-87. doi: 10.1056/NEJMoa1407426. Epub 2014 Sep 7. N Engl J Med. 2014. PMID: 25196020 Free PMC article. Clinical Trial.
Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.
Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA. Heinrich N, et al. Among authors: narunsky k. J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27. J Antimicrob Chemother. 2015. PMID: 25630641 Clinical Trial.
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.
Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium. Boeree MJ, et al. Among authors: narunsky k. Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC. Am J Respir Crit Care Med. 2015. PMID: 25654354 Clinical Trial.
A Step toward an Optimized Rifampin Dose Completed.
Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE. Boeree MJ, et al. Among authors: narunsky k. Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. Am J Respir Crit Care Med. 2015. PMID: 26278799 No abstract available.
High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial.
Boeree MJ, Heinrich N, Aarnoutse R, Diacon AH, Dawson R, Rehal S, Kibiki GS, Churchyard G, Sanne I, Ntinginya NE, Minja LT, Hunt RD, Charalambous S, Hanekom M, Semvua HH, Mpagama SG, Manyama C, Mtafya B, Reither K, Wallis RS, Venter A, Narunsky K, Mekota A, Henne S, Colbers A, van Balen GP, Gillespie SH, Phillips PPJ, Hoelscher M; PanACEA consortium. Boeree MJ, et al. Among authors: narunsky k. Lancet Infect Dis. 2017 Jan;17(1):39-49. doi: 10.1016/S1473-3099(16)30274-2. Epub 2016 Oct 26. Lancet Infect Dis. 2017. PMID: 28100438 Free PMC article. Clinical Trial.
30 results